Lucas José Caram, Francisco Calderon, Esteban Masino, Victoria Ardiles, Ezequiel Mauro, Leila Haddad, Juan Pekolj, Jimena Vicens, Adrian Gadano, Eduardo de Santibañes, Martín de Santibañes. Ann Hepatobiliary Pancreat Surg 2022;26:40-6. https://doi.org/10.14701/ahbps.21-094
Introduction: Even though RAS mutations are known to imply aggressive tumour biology, their objective impact on survival is still controversial. The purpose of this study is to determine the impact of KRAS mutational status in the overall survival (OS) and recurrence free survival (RFS) of patients undergoing surgery for colorectal liver metastases (CLM).